134806-69-2

Upstream product

• 100-52-7 benzaldehyde 
• 92207-60-8 ethyl 2,2-difluoro-3-hydroxy-3-phenylpropanoate 
• 915133-84-5 ethyl 2,2-difluoro-3-{[(methylthio)carbonothioyl]oxy}-3-phenyl propanoate 

Downstream Products

• 503560-25-6 (E)-4,4-difluoro-5-phenyl-2-pentenol 
• 424835-89-2 ethyl (E)-4,4-difluoro-5-phenylpent-2-enoate 
• 875030-90-3 2,2-difluoro-3-phenyl-propionaldehyde 
• 915133-85-6 β,β-difluorobenzenepropanol 

Relevant academic research and scientific papers

Impact of the Difluoromethylene Group in the Organocatalyzed Acylative Kinetic Resolution of α,α-Difluorohydrins

Due to the omnipresence of chiral organofluorine compounds in pharmaceutical, agrochemical, and material chemistry, the development of enantioselective methods for their preparation is highly desirable. In the present study, the enantioselective organocatalyzed acylation of α,α-difluorohydrins using a commercially available chiral isothiourea is reported through a kinetic resolution (KR) process. It reveals that the difluoromethylene moiety (C(sp3)F2) can serve as a directing group through electrostatic fluorine–cation interactions, greatly improving the enantioselectivity of the KR. In this context, a broad range of fluorinated alcohols such as valuable 4,4-difluoro-1,3-diols could be synthesized with exquisite enantiocontrol (typically >99:1 er). Turning to 2,2-difluoro-1,3-diols, we also demonstrated that aromatic and fluorinated groups were mutually compatible to provide the expected enantioenriched adducts with >99:1 er.

DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR

The present invention provides a compound of formula (I) wherein: R1 is a group selected from -CH2OH, -NHC(O)H and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R2; R3 is selected from hydrogen and halogen atoms or groups selected from -SO-R5, -SO2- R5, -NH-CO-NH2, -CO-NH2, hydantoino, C1-4alkyl, C1-4alkoxy and -SO2NR5R6; R4 is selected from hydrogen atoms, halogen atoms and C1-4alkyl groups; R5 is a C1-4alkyl group or C3-8 cycloalkyl; R6 is independently selected from hydrogen atoms and C1-4alkyl groups; n, p and q are independently 0, 1 , 2, 3 or 4; m and s are independently 0, 1 , 2 or 3; r is 0, 1 or 2; with the provisos that: at least one of m and r is not 0; the sum n+m+p+q+r+s is 7, 8, 9, 10, 11 , 12 or 13; the sum q+r+s is 2, 3, 4, 5 or 6 or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.